Core Framework & Diagram The Cancer Immunoediting Theory
July 7, 20261 Min Read Why Does Cancer Relapse?
July 7, 2026Your immune system isn't only eliminating cancer cells — it's simultaneously 'training' them to become more dangerous
—— Cancer immunoediting: why cancer cells get cleverer the harder the immune system hunts them.
I. Elimination phase: the immune system's 'perfect victory'
The 'Elimination phase' is the hardest of the three immunoediting phases to directly observe — because it succeeded. When the immune system effectively clears all cancerous cells in the 'Elimination phase,' the host has no perception, no symptoms, no blood indicator abnormalities, and imaging shows nothing unusual. This battle waged at the cellular level happens and ends completely outside your awareness.
Elimination phase initiation requires several key elements to be simultaneously satisfied: sufficient 'danger signals' — DNA damage and stress in cancerous cells trigger NKG2D ligand upregulation, while releasing HMGB1, ATP, and other 'danger-associated molecular patterns' (DAMPs) activating innate immunity alarms; effective dendritic cell capture and activation — DCs engulf dead cancer cell debris and, under complete co-stimulatory signal conditions, present tumor neoantigens to CD8+ T cells; and sufficient CD4+ Th1 cell assistance — CD4+ T cells provide 'licensing signals' for CTLs through IFN-γ secretion and direct APC activation, enabling CTLs to fully expand and maintain long-term function.
The 'perfection' of the Elimination phase isn't only clearing the immediate cancerous cells — it also establishes immune memory. Some CTLs and tissue-resident memory T cells (Trm) with memory phenotypes remain long-term at the primary site, forming 'long-term sentinel posts.'
2. Equilibrium phase: Darwinian evolution playing out in your body
The 'Equilibrium phase' is the most distinctive and intellectually profound part of immunoediting theory. It elevates 'tumor development' from a simple 'cancer cell proliferation' problem to a 'Darwinian evolution of cancer cells under immune pressure' problem. In the equilibrium phase, cancer cells face a continuous life-or-death test: every cancer cell that can be recognized by CTLs gets killed; every cancer cell that happens to be 'invisible' to CTLs due to random mutation has a higher probability of surviving and continuing to divide. Generation after generation of selection, cells with mutations making them 'unrecognizable by CTLs' gradually gain dominance in the cancer cell population.
The primary evolutionary changes cancer cells accumulate during the equilibrium phase under 'selection pressure' include: neoantigen loss (subclones with highly immunogenic neoantigens are rapidly cleared); MHC-I downregulation (mutations making cancer cells 'invisible to CTLs' are positively selected under immune pressure); enhanced anti-apoptosis mechanisms (cells resistant to perforin/granzyme-mediated apoptosis are preferentially retained); and immune checkpoint ligand upregulation (subclones that can 'brake' entering CTLs via PD-L1 expression have clear survival advantages).
The equilibrium phase can last an extremely long time — in some slow-growing tumors, 'equilibrium' can persist over twenty years, during which a continuous cellular-level evolutionary competition is always underway.
3. Escape phase: when the evolutionary 'winner' breaks through
The escape phase is the equilibrium phase's 'endgame' — one or several cancer cell subclones have accumulated enough immune evasion mutations and, under specific conditions, break through immune control and begin exponential expansion. Triggering conditions often aren't only the cancer cell's own evolution but also changes in host immune status: acute immunosuppressive events (severe infection, major surgery, major psychological trauma) acutely and dramatically suppress NK cell and CTL function via cortisol spikes, giving equilibrium-phase tumors a 'breathing window'; the critical point of immunosenescence — when immune capacity drops below a critical threshold, a tumor that has been in equilibrium for years may rapidly expand in a short time; and tumor microenvironment 'maturation' — as tumor clones evolve, they become increasingly skilled at remodeling their microenvironment, building more sophisticated immunosuppressive systems.
4. Clinical evidence for immunoediting: tumor 'fingerprint' comparisons before and after treatment
Immunoediting theory's most powerful clinical evidence comes from deep sequencing studies of tumors resistant to immune checkpoint inhibitor treatment. A 2017 Science study genomically sequenced non-small cell lung cancer patients' tumors before treatment and after developing resistance to PD-1 inhibitors. Results: in tumors after resistance, cancer cell subclones carrying large amounts of highly immunogenic neoantigens (present before treatment) significantly decreased or disappeared; while subclones lacking strong immunogenic neoantigens, which were only 'minority' before treatment, were 'selectively preserved' during treatment and became the dominant clone after resistance.
Multiple studies also found that in tumors resistant to immune checkpoint inhibitors, the frequency of β2-microglobulin (an essential subunit for MHC-I assembly) gene mutations was significantly higher than before treatment — this mutation causes MHC-I molecules to fail to assemble, making cancer cells completely invisible to CTLs. This type of mutation is strongly positively selected under treatment pressure. These findings have a profound treatment strategy implication: if a single immunotherapy 'trains' tumors to evolve antigen escape, combination strategies simultaneously targeting multiple escape mechanisms may be the better answer to 'immunotherapy-accelerated immunoediting.'
5. Reverse immunoediting: can tumors be pushed 'back' to equilibrium?
Is immunoediting a one-way process from 'Elimination' to 'Equilibrium' to 'Escape'? Or can escaped tumors, under specific conditions, return to 'Equilibrium'? Theoretically, this is possible — if we can simultaneously rebuild the immune system's capacity to recognize the tumor (through individualized neoantigen vaccines providing new 'wanted notices'), remove the immunosuppressive barriers tumors built (through checkpoint inhibitors, targeting TME), and provide powerful T cells (through CAR-T or TCR-T adoptive cell transfer) — essentially simultaneously applying immune pressure from multiple directions, so tumors can't maintain advantage through a single escape strategy.
Clinically, patients with long-term immunotherapy remission are in a sense in exactly this state of 're-established equilibrium' — the tumor hasn't been completely eliminated (sometimes residual lesions are still visible on imaging), but the immune system continuously controls it at a 'symptom-free equilibrium' level. This is the ideal state of 'living with tumor' and an important goal of next-generation cancer immunotherapy: not necessarily needing 'complete elimination,' but needing to maintain durable immune control equilibrium.
6. Immunoediting and cancer screening timing
Immunoediting theory has a specific clinical insight for cancer screening: the optimal time for screening is in the 'Equilibrium phase' — finding cancer while it's still controlled by the immune system, when treatment effect is best, and intervention can prevent the 'Escape phase' from occurring. Waiting until the 'Escape phase' for diagnosis means facing not only a larger tumor but one that has been optimized by immune selection and has greatly enhanced immune evasion capacity — treatment difficulty increases exponentially.
This is also the immunological basis for 'early screening' importance — not only because 'small tumors are easier to treat' (volume consideration), but because 'tumors just entering the escape phase are easier to immune-control than deeply progressed ones' (evolutionary phase consideration). Liquid biopsy (ctDNA) can detect microscopic tumor DNA signals already in the 'Equilibrium phase,' precisely to compensate for traditional imaging's blind spot in this window.
From immunoediting's perspective, 'early' means not only 'the tumor is still small' but also 'the tumor's clonal diversity is still high and immune escape mutations haven't been fully selected and fixed.' Treating in this 'high clonal diversity' window, the immune system has more recognizable targets and higher treatment success rates. The earlier the intervention, the smaller the unfavorable impact immunoediting has on treatment.
Frequently Asked Questions